Zealand Pharma is a Danish biotechnology company that discovers and develops peptide-based medicines, with a strong focus on metabolic diseases such as obesity and type 2 diabetes. Its pipeline and partnered programs target gut-hormone pathways used in next-generation weight-management and endocrine therapies. The business model combines proprietary R&D with collaborations and licensing that can generate milestones and royalties.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 8 | — | -335 | — |
| Q2 2025 | 9,088.3 | — | 7,573.7 | — |
| Q3 2025 | 49.6 | — | -404.2 | — |
| Q4 2025 | 68.9 | — | -379.1 | — |
| Q1 2026 | 34 | 325% | -394 | — |
All markets — KeepWinning global stock screener
Other companies on Copenhagen: TORM plc (TRMD A), Royal Unibrew A/S (RBREW), Ambu A/S (AMBU B), Aktieselskabet Schouw & Co. (SCHO), Bavarian Nordic A/S (BAVA), Netcompany Group A/S (NETC)